UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.476

Sortiert nach

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

JAMA neurology, 2020-02, Vol.77 (2), p.184

2020

Link zum Volltext

Verfügbarkeit prüfen

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

Annals of neurology, 2020-05, Vol.87 (5), p.688-699

2020

Link zum Volltext

Verfügbarkeit prüfen

Effective dose of cone beam CT (CBCT) of the facial skeleton: a systematic review

British journal of radiology, 2015-01, Vol.88 (1045), p.20140658-20140658

2015

Link zum Volltext

Verfügbarkeit prüfen

Epstein–Barr virus infection after adolescence and human herpesvirus 6A as risk factors for multiple sclerosis

European journal of neurology, 2021-02, Vol.28 (2), p.579-586

2021

Link zum Volltext

Verfügbarkeit prüfen

Impaired insulin secretion increases the risk of Alzheimer disease

Neurology, 2008-09, Vol.71 (14), p.1065

2008

Link zum Volltext

Verfügbarkeit prüfen

Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy

Journal of neurology, neurosurgery and psychiatry, 2024, Vol.95 (2), p.134

2024

Link zum Volltext

Verfügbarkeit prüfen

Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis—a presymptomatic case–control study

European journal of neurology, 2021-09, Vol.28 (9), p.3072-3079

2021

Link zum Volltext

Verfügbarkeit prüfen

Optimization of energy and directional response of a small 4π silicon dosemeter for quality control of CT/CBCT-units – A 3D CAD, Monte-Carlo, AM approach

Applied radiation and isotopes, 2020-04, Vol.158, p.109050-109050, Article 109050

2020

Link zum Volltext

Verfügbarkeit prüfen

High tau levels in cerebrospinal fluid predict rapid decline and increased dementia mortality in Alzheimer's disease

Dementia and geriatric cognitive disorders, 2014-01, Vol.37 (3-4), p.196

2014

Link zum Volltext

Verfügbarkeit prüfen

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society

Acta neurologica Scandinavica, 2017-01, Vol.135 (1), p.17-24

2017

Link zum Volltext

Verfügbarkeit prüfen

Building implementation capacity (BIC): a longitudinal mixed methods evaluation of a team intervention

BMC health services research, 2019-05, Vol.19 (1), p.287-287, Article 287

2019

Link zum Volltext

Verfügbarkeit prüfen

Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease

Dementia and geriatric cognitive disorders, 2007-01, Vol.24 (4), p.247

2007

Link zum Volltext

Verfügbarkeit prüfen

Neurofilament and glial fibrillary acidic protein in multiple sclerosis

Neurology, 2004-11, Vol.63 (9), p.1586

2004

Link zum Volltext

Verfügbarkeit prüfen

Icy grains as a source of CO in comet 29P/Schwassmann-Wachmann 1

Astronomy and astrophysics (Berlin), 2003-01, Vol.398 (1), p.353-361

Gunnarsson, M.

2003

Link zum Volltext

Verfügbarkeit prüfen

Characteristics in childhood and adolescence associated with future multiple sclerosis risk in men: cohort study

European journal of neurology, 2015-07, Vol.22 (7), p.1131-1137

2015

Link zum Volltext

Verfügbarkeit prüfen

SARS-COV2 exposure rates and serological response of people living with MS

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (3_SUPPL), p.515

2022

Link zum Volltext

Verfügbarkeit prüfen

A Swedish Nationwide study of the long-term effectiveness and safety of teriflunomid based on data from the Swedish "Immunomodulation and Multiple Sclerosis Epidemiology" Study (IMSE 4)

MULTIPLE SCLEROSIS JOURNAL, 2019, Vol.25 (Suppl. 2), p.316

2019

Link zum Volltext

Verfügbarkeit prüfen

A Swedish real word study of the long-term effectiveness and safety of fingolimod (IMSE 2) with focus on patients treated at least 48 months

MULTIPLE SCLEROSIS JOURNAL, 2019, Vol.25 (Suppl. 2), p.536

2019

Link zum Volltext

Verfügbarkeit prüfen

A swedish post-market surveillance study of the long-term effectiveness and safety of alemtuzumab (IMSE 3) for patients treated at least 24 months

MULTIPLE SCLEROSIS JOURNAL, 2019, Vol.25 (Suppl. 2), p.327

2019

Link zum Volltext

Verfügbarkeit prüfen

Glucose metabolism and the risk of Alzheimer's disease and dementia: a population-based 12 year follow-up study in 71-year-old men

Diabetologia, 2009-08, Vol.52 (8), p.1504-1510

2009

Link zum Volltext

Verfügbarkeit prüfen

COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls

Annals of clinical and translational neurology, 2022-09, Vol.9 (9), p.1449-1458

2022

Link zum Volltext

Verfügbarkeit prüfen

Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort

Multiple sclerosis and related disorders, 2023, Vol.70, p.104481-104481, Article 104481

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical effectiveness of dimethyl fumarate with focus on patients treated at least 36 months - a Swedish nationwide study of the long-term effectiveness and safety of dimethyl fumarate (IMSE5)

MULTIPLE SCLEROSIS JOURNAL, 2019, Vol.25 (Suppl. 2), p.316

2019

Link zum Volltext

Verfügbarkeit prüfen

Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study

Dementia and geriatric cognitive disorders, 2010-01, Vol.29 (3), p.204

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.476

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.275)
Mit Volltextzugriff
(1.373)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

Effective dose of cone beam CT (CBCT) of the facial skeleton: a systematic review

Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial

Epstein–Barr virus infection after adolescence and human herpesvirus 6A as risk factors for multiple sclerosis

Impaired insulin secretion increases the risk of Alzheimer disease

Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy

Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis—a presymptomatic case–control study

Optimization of energy and directional response of a small 4π silicon dosemeter for quality control of CT/CBCT-units – A 3D CAD, Monte-Carlo, AM approach

High tau levels in cerebrospinal fluid predict rapid decline and increased dementia mortality in Alzheimer's disease

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society

Building implementation capacity (BIC): a longitudinal mixed methods evaluation of a team intervention

Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease

Neurofilament and glial fibrillary acidic protein in multiple sclerosis

Icy grains as a source of CO in comet 29P/Schwassmann-Wachmann 1

Characteristics in childhood and adolescence associated with future multiple sclerosis risk in men: cohort study

SARS-COV2 exposure rates and serological response of people living with MS

A Swedish Nationwide study of the long-term effectiveness and safety of teriflunomid based on data from the Swedish "Immunomodulation and Multiple Sclerosis Epidemiology" Study (IMSE 4)

A Swedish real word study of the long-term effectiveness and safety of fingolimod (IMSE 2) with focus on patients treated at least 48 months

A swedish post-market surveillance study of the long-term effectiveness and safety of alemtuzumab (IMSE 3) for patients treated at least 24 months

Glucose metabolism and the risk of Alzheimer's disease and dementia: a population-based 12 year follow-up study in 71-year-old men

COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls

Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort

Clinical effectiveness of dimethyl fumarate with focus on patients treated at least 36 months - a Swedish nationwide study of the long-term effectiveness and safety of dimethyl fumarate (IMSE5)

Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study

Suchergebnisse filtern